Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 12/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5133328 | 0.85 | CRHR1 (0.32) | CRHR1ADORA1HTR2BADORA3ADORA2A | |
| SCHEMBL5049278 | 0.79 | KDM4E (0.37) | CRHR1ALDH1A1 | |
| SCHEMBL5626968 | 0.77 | BCDIN3D (0.35) | CRHR1ADORA1ADORA3ADORA2AALDH1A1 | |
| SCHEMBL5049413 | 0.75 | CRHR1 (0.35) | CRHR1ADORA1ADORA3 | |
| SCHEMBL5624330 | 0.73 | CRHR1 (0.40) | CRHR1ADORA1HTR2BADORA3ADORA2A | |
| SCHEMBL5132599 | 0.72 | CRHR1 (0.36) | CRHR1ADORA1HTR2BADORA3ADORA2A | |
| SCHEMBL5043548 | 0.66 | IRAK4 (0.40) | ALDH1A1 | |
| SCHEMBL5625128 | 0.66 | TACR1 (0.38) | — | |
| SCHEMBL20113952 | 0.64 | CYP1A2 (0.39) | ALDH1A1 | |
| SCHEMBL10735089 | 0.63 | CYP3A4 (0.59) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782407-B2 | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-10-10 | — | — | US | disclosed |
| US-9765030-B2 | Benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-09-19 | — | — | US | disclosed |
| EP-1848430-B1 | NOVEL BENZYLAMINE DERIVATIVES AS CETP INHIBITORS | Dr Reddys Laboratories Ltd (IN) | 2017-08-02 | — | — | EP | disclosed |
| US-20150216866-A1 | SUBSTITUTED BENZYLAMINO QUINOLINES AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-08-06 | — | — | US | disclosed |
| US-9040558-B2 | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-05-26 | — | — | US | disclosed |
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-05-15 | — | — | US | disclosed |
| US-8604055-B2 | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2013-12-10 | — | — | US | disclosed |
| EP-1848430-A2 | NOVEL BENZYLAMINE DERIVATIVES AS CETP INHIBITORS | Reddy US Therapeutics, Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
| US-20060178514-A1 | Novel benzylamine derivatives as CETP inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-08-10 | — | — | US | disclosed |
| WO-2006073973-A2 | NOVEL BENZYLAMINE DERIVATIVES AS CETP INHIBITORS | REDDY US THERAPEUTICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | CETP, NPC1, DBI | CRHR1 4802/4885ADORA1 4087/4885HTR2B 3770/4885 |
| US-20150216866-A1 | SUBSTITUTED BENZYLAMINO QUINOLINES AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | CETP, NPC1, MTTP | CRHR1 4672/4885ADORA1 3499/4885HTR2B 2300/4885 |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | CETP, NPC1, DBI | CRHR1 4802/4885ADORA1 4087/4885HTR2B 3770/4885 |
| US-20060178514-A1 | Novel benzylamine derivatives as CETP inhibitors | CETP, NPC1, LIPC | CRHR1 4536/4885ADORA1 2644/4885HTR2B 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.